Trilaciclib

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.

The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.

Journal: Immunotherapy

Published: September 11, 2025

Case Report: Analysis of short-term clinical efficacy of trilaciclib in patients with advanced lung neuroendocrine carcinoma undergoing chemotherapy.

Case Report: Analysis of short-term clinical efficacy of trilaciclib in patients with advanced lung neuroendocrine carcinoma undergoing chemotherapy.

Journal: Frontiers in oncology

Published: August 14, 2025

Application value and safety of trilaciclib in first-line chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer: A real-world study.

Application value and safety of trilaciclib in first-line chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer: A real-world study.

Journal: Oncology letters

Published: May 23, 2025

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Journal: Pharmacological research

Published: March 29, 2025

HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib.

HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.

Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: March 10, 2025

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Journal: Cell reports. Medicine

Published: February 21, 2025

Real-World Clinical Outcomes of Trilaciclib for the Prevention of Myelosuppression in Patients with Esophageal Cancer Undergoing Chemotherapy.

Real-World Clinical Outcomes of Trilaciclib for the Prevention of Myelosuppression in Patients with Esophageal Cancer Undergoing Chemotherapy.

Journal: Current oncology (Toronto, Ont.)

Published: February 11, 2025

Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials.

Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials.

Journal: Translational lung cancer research

Published: January 25, 2025

Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression.

Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression.

Journal: Journal of medicinal chemistry

Published: January 06, 2025

Real-World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.

Real-World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.

Journal: Cancer medicine

Published: November 12, 2024

Showing 1-12 of 77

Last Updated: 02/24/2026